{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:08:57Z","timestamp":1790096937924,"version":"4.0.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.drudis.2026.104763","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T23:48:33Z","timestamp":1786492113000},"page":"104763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reassessing R&D outcomes of leading pharmaceutical companies"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7884-5757","authenticated-orcid":false,"given":"Alexander","family":"Schuhmacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Witting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Hartl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Gassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104763_b0005","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2307\/2233907","article-title":"Industrial economics: an overview","volume":"98","author":"Schmalensee","year":"1988","journal-title":"Econ J"},{"key":"10.1016\/j.drudis.2026.104763_b0010","first-page":"14","article-title":"Economics of the pharmaceutical industry","author":"Danzon","year":"2006","journal-title":"NBER Report"},{"key":"10.1016\/j.drudis.2026.104763_b0015","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1257\/jel.20161327","article-title":"Economics of the pharmaceutical industry","volume":"56","author":"Lakdawalla","year":"2018","journal-title":"J Econ Lit"},{"key":"10.1016\/j.drudis.2026.104763_b0020","series-title":"Competitive Advantage: Creating and Sustaining Superior Performance","author":"Porter","year":"1985"},{"key":"10.1016\/j.drudis.2026.104763_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103726","article-title":"Analysis of pharma R&D productivity: a new perspective needed","volume":"28","author":"Schuhmacher","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104763_b0030","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/smj.229","article-title":"Sources of capabilities, integration and technology commercialization","volume":"23","author":"Zahra","year":"2002","journal-title":"Strateg Manag J"},{"key":"10.1016\/j.drudis.2026.104763_b0035","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104763_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104494","article-title":"The R&D productivity challenge: transforming the pharmaceutical ecosystem","volume":"30","author":"Schuhmacher","year":"2025","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104763_b0045","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3681","article-title":"Diagnosing the decline in pharmaceutical R&D efficiency","volume":"11","author":"Scannell","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104763_b0050","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/d41573-024-00068-6","article-title":"Efficiency, effectiveness and productivity in pharmaceutical R&D","volume":"23","author":"Roland","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104763_b0055","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nrd3405","article-title":"The productivity crisis in pharmaceutical R&D","volume":"10","author":"Pammolli","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104763_b0060","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: new estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J Health Econ"},{"key":"10.1016\/j.drudis.2026.104763_b0065","article-title":"Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006\u20132022)","volume":"30","author":"Schuhmacher","year":"2025","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104763_b0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrd4497","article-title":"A decade of innovation in pharmaceutical R&D: the Chorus model","volume":"14","author":"Owens","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104763_b0075","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd.2017.244","article-title":"Impact of a five-dimensional framework on R&D productivity at AstraZeneca","volume":"17","author":"Morgan","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104763_b0080","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.drudis.2021.12.010","article-title":"Achieving end-to-end success in the clinic: Pfizer\u2019s learnings on R&D productivity","volume":"27","author":"Fernando","year":"2022","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104763_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103952","article-title":"Accelerating drug development at Bristol Myers Squibb through innovation","volume":"29","author":"Viraswami-Appanna","year":"2024","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104763_b0090","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/d41573-022-00213-z","article-title":"The significance of blockbusters in the pharmaceutical industry","volume":"22","author":"Schuhmacher","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104763_b0095","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3111\/13696998.2013.873723","article-title":"Recent trends in brand-name and generic drug competition","volume":"17","author":"Grabowski","year":"2014","journal-title":"J Med Econ"},{"key":"10.1016\/j.drudis.2026.104763_b0100","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nbt.2947","article-title":"Benchmarking biotech and pharmaceutical product development","volume":"32","author":"Drakeman","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2026.104763_b0105","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1509\/jmkg.67.4.82.18687","article-title":"Sources and financial consequences of radical innovation: insights from pharmaceuticals","volume":"67","author":"Sorescu","year":"2003","journal-title":"J Mark"},{"key":"10.1016\/j.drudis.2026.104763_b0110","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/clpt.2013.115","article-title":"Defining innovativeness in drug development: a systematic review","volume":"94","author":"Kesselheim","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104763_b0115","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrd4336","article-title":"The discovery of first-in-class drugs: origins and evolution","volume":"13","author":"Eder","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104763_b0120","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0167-6296(01)00108-4","article-title":"Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research","volume":"20","author":"Cockburn","year":"2001","journal-title":"J Health Econ"},{"key":"10.1016\/j.drudis.2026.104763_b0125","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0883-9026(01)00069-6","article-title":"The effects of business-university alliances on innovative output and financial performance: a study of publicly traded biotechnology companies","volume":"17","author":"George","year":"2002","journal-title":"J Bus Venturing"},{"key":"10.1016\/j.drudis.2026.104763_b0130","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/nrd3251","article-title":"The importance of new companies for drug discovery: origins of a decade of new drugs","volume":"9","author":"Kneller","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104763_b0135","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.techfore.2012.06.007","article-title":"Big pharma, little science? A bibliometric perspective on Big Pharma\u2019s R&D decline","volume":"81","author":"Rafols","year":"2014","journal-title":"Technol Forecast Soc Change"},{"key":"10.1016\/j.drudis.2026.104763_b0140","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0167-6296(02)00126-1","article-title":"The price of innovation: new estimates of drug development costs","volume":"22","author":"DiMasi","year":"2003","journal-title":"J Health Econ"},{"key":"10.1016\/j.drudis.2026.104763_b0145","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hec.1454","article-title":"Spending on new drug development","volume":"19","author":"Adams","year":"2010","journal-title":"Health Econ"},{"key":"10.1016\/j.drudis.2026.104763_b0150","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1377\/hlthaff.25.2.420","article-title":"Estimating the cost of new drug development: is it really $802 million?","volume":"25","author":"Adams","year":"2006","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.drudis.2026.104763_b0155","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/mde.1360","article-title":"The cost of biopharmaceutical R&D: is biotech different?","volume":"28","author":"DiMasi","year":"2007","journal-title":"Manag Decis Econ"},{"key":"10.1016\/j.drudis.2026.104763_b0160","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.53275","article-title":"Use of clinical trial characteristics to estimate costs of new drug development","volume":"8","author":"Mulcahy","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.drudis.2026.104763_b0165","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.15445","article-title":"Costs of drug development and research and development intensity in the US, 2000\u20132018","volume":"7","author":"Sertkaya","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.drudis.2026.104763_b0170","first-page":"114","article-title":"Can science be a business? Lessons from biotech","volume":"84","author":"Pisano","year":"2006","journal-title":"Harv Bus Rev"},{"key":"10.1016\/j.drudis.2026.104763_b0175","first-page":"837","article-title":"Big pharma moves from blockbusters to niche busters","volume":"16","author":"Dolgin","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104763_b0180","series-title":"Pharma R&D Annual Review 2024","author":"Lloyd","year":"2024"},{"key":"10.1016\/j.drudis.2026.104763_b0185","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1001\/jama.2022.5542","article-title":"Trends in prescription drug launch prices, 2008\u20132021","volume":"327","author":"Rome","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2026.104763_b0190","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1038\/s41598-024-53554-7","article-title":"Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980\u20132022","volume":"14","author":"Seoane-Vazquez","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104763_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2026.104677","article-title":"New perspectives for better R&D performance: lessons learned from leading pharma companies","volume":"31","author":"Schuhmacher","year":"2026","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104763_b0200","first-page":"137","article-title":"How a firm\u2019s capabilities affect boundary decisions","volume":"40","author":"Barney","year":"1999","journal-title":"MIT Sloan Management Review"},{"key":"10.1016\/j.drudis.2026.104763_b0205","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1467-8551.1991.tb00014.x","article-title":"Key characteristics of the large innovating firm","volume":"2","author":"Pavitt","year":"1991","journal-title":"Br J Manage"},{"key":"10.1016\/j.drudis.2026.104763_b0210","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2026.104763_b0215","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrd.2017.114","article-title":"What is the right amount to spend on biopharma R&D?","volume":"16","author":"Ringel","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104763_b0220","unstructured":"FDA. Designating an Orphan Product: Drugs and Biological Products. US Food and Drug Administration. Published 2 Nov 2025. https:\/\/www.fda.gov\/industry\/medical-products-rare-diseases-and-conditions\/designating-orphan-product-drugs-and-biological-products."},{"key":"10.1016\/j.drudis.2026.104763_b0225","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nrd4035","article-title":"What matters most in commercial success: first-in-class or best-in-class?","volume":"12","author":"Schulze","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104763_b0230","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/d41573-022-00025-1","article-title":"AI in small-molecule drug discovery: a coming wave?","volume":"21","author":"Jayatunga","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104763_b0235","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12553-023-00738-2","article-title":"Artificial intelligence applied to clinical trials: opportunities and challenges","volume":"13","author":"Askin","year":"2023","journal-title":"Health Technol"},{"key":"10.1016\/j.drudis.2026.104763_b0240","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drudis.2020.10.010","article-title":"Artificial intelligence in drug discovery and development","volume":"26","author":"Paul","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104763_b0245","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/nrd4127","article-title":"Pharmaceutical forecasting: throwing darts?","volume":"12","author":"Cha","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104763_b0250","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/d41573-023-00102-z","article-title":"Investigating the origins of recent pharmaceutical innovation","volume":"22","author":"Schuhmacher","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104763_b0255","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41587-024-02506-7","article-title":"Biopharma deals get smaller and earlier","volume":"43","author":"Senior","year":"2025","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2026.104763_b0260","doi-asserted-by":"crossref","unstructured":"Biotech mega-deals boost Pfizer, Sanofi pipelines. Nat Biotechnol. 2023;41:439. https:\/\/doi.org\/10.1038\/s41587-023-01761-4.","DOI":"10.1038\/s41587-023-01761-4"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:15:28Z","timestamp":1790093728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626001686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1359644626001686"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104763","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reassessing R&D outcomes of leading pharmaceutical companies","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104763","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104763"}}